Trial Profile

A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Status: Suspended

Phase of Trial: Phase II/III

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Tiragolumab (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms SKYSCRAPER-06
Sponsors Roche

07 Mar 2025 Planned End Date changed from 14 May 2027 to 30 Sep 2025.
07 Mar 2025 Planned primary completion date changed from 29 Dec 2025 to 30 Sep 2025.
11 Dec 2024 Planned primary completion date changed from 14 May 2027 to 29 Dec 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com